Key result
Allogeneic hematopoietic stem cell transplantation resulted in significant elevations of plasma NT-proBNP and hs-cTnT levels over 30 days (P < 0.01), preceding clinical signs of cardiotoxicity.
Why the study?
Do serial measurements of NT-proBNP and hs-cTnT detect subclinical myocardial damage and identify patients at risk of clinical cardiotoxicity after allogeneic HSCT?
Observational (n=37)
No
Do serial measurements of NT-proBNP and hs-cTnT detect subclinical myocardial damage and identify patients at risk of clinical cardiotoxicity after allogeneic HSCT?
p-value: p=<0.01
Persistent elevations in NT-proBNP and hs-cTnT for more than 14 days after allogeneic HSCT can identify patients at high risk for developing clinical cardiotoxicity.
Serial NT-proBNP/hs-cTnT monitoring may flag subclinical cardiotoxicity risk after allogeneic HSCT; hypothesis-generating and requires prospective validation before practice change.
No takes yet. Share an insight, caveat, or question.
Roziaková et al. (2012) conducted an observational in Hematologic diseases requiring allogeneic hematopoietic stem cell transplantation (n=37). Allogeneic hematopoietic stem cell transplantation vs. Baseline (before conditioning regimen) was evaluated on Changes in plasma NT-proBNP and hs-cTnT levels during the 30 days following HSCT (p=<0.01). Allogeneic hematopoietic stem cell transplantation resulted in significant elevations of plasma NT-proBNP and hs-cTnT levels over 30 days (P < 0.01), preceding clinical signs of cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: